Contrast-induced nephropathy

Journal of Endovascular Therapy

Volumn 14, Issue 1, 2007, Pages 92-100

  Walsh, Stewart R ^a   Tang, Tjun ^a   Gaunt, Michael E ^a   Boyle, Jonathan R ^a,b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Contrast media; Nephropathy; Prophylaxis; Renal insufficiency; Risk factors

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE; AMINOPHYLLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; FUROSEMIDE; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; THEOPHYLLINE;

CARDIOVASCULAR PROCEDURES; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; ENDOVASCULAR THERAPY; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYDRATION; IATROGENIC DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; MEDLINE; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLICATION; REHYDRATION; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW;

BLOOD VOLUME; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; HEMOFILTRATION; HUMANS; PRACTICE GUIDELINES; PROTECTIVE AGENTS; RADIOGRAPHY, INTERVENTIONAL; RENAL DIALYSIS; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; VASCULAR SURGICAL PROCEDURES;

EID: 33847207145     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/06-2035.1     Document Type: Review

References (81)

1. Persson PD. Contrast medium induced nephropathy. Nephrol Dial Transplant. 2005;20(Suppl 1):ii.
2. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-936.
3. Thomsen HS, Morcos SK. Contrast media and the kidney. European Society of Urogential Radiology (ESUR) guidelines. Br J Radiol. 2003;76:513-518.
4. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration. Radiology. 1997;203:605-610.
5. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
6. Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40:1136-1141.
7. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
8. Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98(Suppl 1):14-20.
9. Lindholt JS. Radiocontrast induced nephropathy. Eur J Vasc Endovasc Surg. 2003;25:296-304.
10. Morris TW, Katzberg RW, Fischer HW. A comparison of the hemodynamic responses to metrizamide and meglumine/sodium diatrizoate in canine renal angiography. Invest Radiol. 1978;13:74-78.
11. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol. 2002;37:428-434.
12. Haller C, Hizoh I. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol. 2004;39:149-154.
13. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
14. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90:1068-1073.
15. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003;15:18-22.
16. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67:706-713.
17. Nikolsky E, Aymong ED, Dangas G, et al. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med. 2003;4(Suppl 1):S7-S14.
18. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res. 1992;53:317-320.
19. Lameire N, Adam A, Becker CR, et al. Baseline renal function screening. Am J Cardiol. 2006;98(Suppl 1):21-26.
20. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. 2006;100(Suppl):S11-S15.
21. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94:300-305.
22. Berns AS. Nephrotoxicity of contrast media. Kidney Int. 1989;36:730-740.
23. Gussenhoven MJ, Ravensbergen J, van Bockel JH, et al. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg. 1991;32:81-86.
24. Cirillo M, Laurenzi M, Mancini M, et al. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006;70:800-806.
25. Meschi M, Detrenis S, Musini S, et al. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med. 2006;34:2060-2068.
26. Vlietstra RE, Nunn CM, Narvarte J, et al. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J. 1996;132:1049-1050.
27. Manske CL, Sprafka JM, Strony JT, et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89:615-620.
28. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171-178.
29. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int. 1995;47:254-261.
30. Aspelin P, Aubry P, Franson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.
31. Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol. 1998;8:144-147.
32. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study, a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-930.
33. Deray G. Nephrotoxicity of contrast media. Nephrol Dial Transplant. 1999;14:2602-2606.
34. Idee JM, Beaufils H, Bonnemain B. Iodinated contrast media-induced nephropathy: pathophysiology, clinical aspects and prevention. Fundam Clin Pharmacol. 1994;8:193-206.
35. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
36. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983;141:1027-1033.
37. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(Suppl):27-36.
38. McCullough PA, Stacul F, Davidson C, et al. Overview. Am J Cardiol. 2006;98(Suppl 1):2-4.
39. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int. 2006;100(Suppl):S51-53.
40. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(Suppl 1):59-77.
41. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant. 1999;14:1064-1066.
42. Taylor AJ, Hotchkiss D, Morse RW, et al. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114:1570-1574.
43. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93: C29-34.
44. Dussol B, Morange S, Loundoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006;21:2120-2126.
45. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62:1-7.
46. Krasuski RA, Beard BM, Geoghagan JD, et al. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699-702.
47. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
48. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
49. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-2334.
50. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int. 2006;100(Suppl):S16-19.
51. Shammas NW, Kapalis MJ, Harris M, et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol. 2001;13:738-740.
52. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260-263.
53. Tsao CR, Liu TJ, Chen FC, et al. Intravenous aminophylline provides no additional renal protection in patient with severe atherosclerotic renal artery stenosis treated by delicate percutaneous renal intervention. Int J Cardiol. 2006;110:122-124.
54. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast induced nephropathy: a systematic review and meta-analysis. Arch Intern Med. 2005;165:1087-1093.
55. Briguori C, Marenzi G. CIN pharmacological prophylaxis. Kidney Int. 2006;69:S30-S38.
56. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837-2842.
57. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92:1454-1458.
58. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
59. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004;43:1-9.
60. Nallamothou B, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117:938-947.
61. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761-769.
62. Zagler A, Azadpour M, Mercado C, et al. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151:140-145.
63. Sandhu C, Belli AM, Oliveira DB. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol. 2006;29:344-347.
64. Moore NM, Lapsley M, Norden AG, et al. Does N-acetylcysteine prevent contrast induced nephropathy during endovascular AAA repair? A randomised controlled pilot study. J Endovasc Ther. 2006;13:660-666.
65. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992;62:413-415.
66. Khanal S, Attallah N, Smith DE, et al. Stalin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843-849.
67. Attallah N, Yassine L, Musial J, et al. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62:273-278.
68. Huber W, Jeschke B, Kreymann B, et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol. 2002;37:471-481.
69. Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003;60:176-182.
70. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-1340.
71. Alsac JM, Zarins CK, Heikkinen MA, et al. The impact of aortic endografts on renal function. J Vasc Surg. 2005;41:926-930.
72. Surowiec SM, Davies MG, Fegley AJ, et al. Relationship of proximal fixation to postoperative renal dysfunction in patients with normal serum creatinine concentration. J Vasc Surg. 2004;39:804-810.
73. Arko FR, Filis KA, Heikkinen MA, et al. Duplex scanning after endovascular aneurysm repair: an alternative to computed tomography. Semin Vasc Surg. 2004;17:161-165.
74. Sun Z. Diagnostic value of color duplex ultrasonography in the follow-up of endovascular repair of abdominal aortic aneurysm. J Vasc Interv Radiol. 2006;17:759-764.
75. Ascher E, Marks NA, Schutzer RW, et al. Duplex-guided balloon angioplasty and stenting for femoropopliteal arterial occlusive disease: an alternative in patients with renal insufficiency. J Vasc Surg. 2005;42:1108-1113.
76. Ascher E, Marks NA, Hingorani AP, et al. Duplex-guided balloon angioplasty and subintimal dissection of infrapopliteal arteries: early results with a new approach to avoid radiation exposure and contrast material. J Vasc Surg. 2005;42:1114-1121.
77. Shaw DR, Kessel DO. The current status of the use of carbon dioxide in diagnostic and interventional angiographic procedures. Cardiovasc Intervent Radiol. 2006;29:323-331.
78. Neschis DG, Fairman RM. Magnetic resonance imaging for planning aortic endograft procedures. Semin Vasc Surg. 2004;17:135-143.
79. Ozturk C, Guttman M, McVeigh ER, et al. Magnetic resonance imaging-guided vascular interventions. Top Magn Reson Imaging. 2005;16:369-381.
80. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
81. Nyman U, Elmstahl B, Leander P, et al. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology. 2002;223:311-319.